Use of Palifermin in Allogeneic Stem Cell Transplantation (SCT) for Patients with Acute Lymphoblastic Leukemia (ALL)
Year: 2009
Type: article
Abstract: Background: Palifermin is a recombinant keratinocyte growth factor (KGF) approved to decrease the incidence and severity of mucositis in stem cell transplantation. Furthermore, effects on the KGF receptor may modulate and minimize acute GVHD. Studies utilizing palifermin have been conducted in autologous SCT; however, literature regarding use in allogeneic SCT is minimal.
Authors: J.E. Anderson, A.M. Gulbis, R.M. Cool, M.D. Westmoreland, M. de Lima, S. Giralt, C. Hosing, U. Popat, M.H. Qazilbash, E. Shpall, I.F. Khouri, R. Champlin, P. Kebriaei
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2076489926